Dr. Chuang will discuss the SCA3 ASO (anti-sense oligonucleotide) study that is currently recruiting, review important aspects of Biogen’s clinical trial, and discuss how the drug will be studied for Ataxia.

About Dr. Rosalind Chuang:
Dr. Rosalind Chuang is movement disorders neurologist who is currently a Medical Director in Early Clinical Development in the PD/Movement Disorders Neurodegeneration Unit at Biogen. She has longstanding research and clinical interest in Ataxia, first serving as the director of the Stanford University’s Multi-Disciplinary Huntington’s Disease and Ataxia Clinic and subsequently seeing complex movement disorders in a tertiary care hospital in Seattle, WA. A long time participant of NAF, since joining Biogen in in September 2020, she has been working to bring Ataxia trials to patients.

Link to Register: https://us02web.zoom.us/meeting/register/tZIlcOqqqz4sGNQEofT_cC6gZsxdfD3KkiWB